Clearside Biomedi (CLSD) Stock Price, Quote & News

Company Profile

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which has completed Phase 2 clinical trial to treat wet AMD. The company has a collaboration with bausch...

Industry: Biotechnology

Sector: Healthcare

Phone: 678 270 3631

Fax: 678 270 4033

Website: clearsidebio.com

Address:

900 North Point Parkway, Suite 200, Alpharetta, United States

BioRich Jun. 21 at 3:58 AM

$CLSD Seriously, what's the Bear case here? They haver partnerships. They have FDA approvals. They have pipeline. How is this under a buck? I'm new to this and blinded by positivity so someone please help ground me. Thanks! https://ir.clearsidebio.com/news-releases/news-release-details/clearside-biomedical-announces-multiple-presentations-be

1 · Reply

BioRich Jun. 21 at 1:03 AM

$CLSD Feeling very fortunate to get in on this gem before it goes on a triple digit run. Locked and loaded on this low float. Hope you are too! Follow/Subscribe for more suggestions and perspective. Would love to hear yours, too. That's how we find these gems and learn. Let's make some money. Cheers! ~BioRich Capital $XBI $JNJ $PFE $GILD

1 · Reply

JWMM Jun. 20 at 8:03 PM

$CLSD big spike in volume and price at the close????

2 · Reply

BioRich Jun. 20 at 1:37 PM

$CLSD Does this have Phase 3 data readout tomorrow?

1 · Reply

Qora Jun. 19 at 2:06 PM

$CLSD wanted to start a discussion on other suprachoroidal delivery devices companies filed patents for. Implications of this vs. the breadth of SCS patents that Clearside has.

2 · Reply

maphere Jun. 19 at 1:12 PM

$CLSD yep...a great article to start the day... A new type of injection could improve eye disease treatment https://www.drugdiscoverynews.com/a-new-type-of-injection-could-improve-eye-disease-treatment-16458

1 · Reply

rando321456 Jun. 18 at 8:01 AM

$CLSD $AURA It was a few weeks ago but when Aura's ceo was talking about pricing they referenced the approved drug for the choroidal melanoma that has spread, which goes for about 600k before the patient dies. Am I off my rocker thinking that between choroidal melanoma and mets that they will just be doing 5 billion dollars in revenue if the data pattern holds?

1 · Reply

maphere Jun. 17 at 2:34 PM

$CLSD This year they announce presentations ahead of the Clinical Trials at the Summit (17th PR, 21st Presentations). https://ir.clearsidebio.com/news-releases/news-release-details/clearside-biomedical-announces-multiple-presentations-be Last year the presentations were on June 8th and the post PR was on the 12th four days after the event. https://ir.clearsidebio.com/news-releases/news-release-details/clearside-biomedicals-leadership-suprachoroidal-delivery So confusing...

2 · Reply

maphere Jun. 15 at 12:45 AM

$CLSD Patent updates: US20250177417 - COMPOSITIONS AND METHODS FOR TREATING MACULAR EDEMA ASSOCIATED WITH UVEITIS https://patentscope.wipo.int/search/en/detail.jsf?docId=US457343234&_cid=P10-MBWVK3-05508-1 US20250177201 - DEVICE FOR OCULAR ACCESS https://patentscope.wipo.int/search/en/detail.jsf?docId=US457343018&_cid=P10-MBWXYJ-64961-1 EP4566672 - METHODS FOR THE TREATMENT OF OCULAR DISEASE IN HUMAN SUBJECTS https://patentscope.wipo.int/search/en/detail.jsf?docId=EP457575093&_cid=P10-MBWXYJ-64961-1

1 · Reply

wishpotion Jun. 13 at 2:33 PM

$CLSD One thing is for sure at this point. A step which would bring a smaller amount of money, to buy more time again will make things even worse then better. That is why I hope there must be something important and most likely for CLSD strategically significant in work.

0 · Reply

Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting

May 21, 2025, 7:05 AM EDT - 4 weeks ago

Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum

May 14, 2025, 4:05 PM EDT - 5 weeks ago

Clearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate Update

May 9, 2025, 7:05 AM EDT - 6 weeks ago

Clearside Biomedical Data Featured in Six Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

May 8, 2025, 7:05 AM EDT - 6 weeks ago

Clearside Biomedical to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025

May 1, 2025, 7:05 AM EDT - 7 weeks ago

Clearside Biomedical to Participate in a Fireside Chat at the Citizens Life Sciences Conference

Apr 1, 2025, 7:05 AM EDT - 2 months ago

Clearside Biomedical to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

Mar 27, 2025, 8:31 PM EDT - 3 months ago

Clearside Biomedical, Inc. (CLSD) Q4 2024 Earnings Conference Call Transcript

Mar 27, 2025, 4:05 PM EDT - 3 months ago

Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 24, 2025, 7:05 AM EDT - 3 months ago

Clearside Biomedical Announces Six Abstracts Accepted for Presentation at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

Mar 20, 2025, 7:05 AM EDT - 3 months ago

Clearside Biomedical's Lead Clinical Program CLS-AX in Wet AMD and Suprachoroidal Delivery Platform Highlighted at the 2025 Wet AMD & Diabetic Eye Disease Summit

Mar 12, 2025, 7:05 AM EDT - 3 months ago

Clearside Biomedical to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on Thursday, March 27, 2025

Mar 6, 2025, 7:05 AM EST - 3 months ago

Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMD

Feb 20, 2025, 7:05 AM EST - 4 months ago

Clearside Biomedical's Asia-Pacific Partner, Arctic Vision, Announced Acceptance of its New Drug Application for ARCATUS® for Regulatory Review in China for the Treatment of Uveitic Macular Edema

Feb 10, 2025, 7:05 AM EST - 4 months ago

Clearside Biomedical Announces Additional Data from the CLS-AX ODYSSEY Phase 2b Trial Presented at the Angiogenesis, Exudation, and Degeneration 2025 Meeting

Feb 4, 2025, 7:05 AM EST - 4 months ago

Clearside Biomedical to Participate in Fireside Chat at the Oppenheimer 35th Annual Healthcare Life Sciences Virtual Conference

Jan 28, 2025, 7:05 AM EST - 5 months ago

Clearside Biomedical Announces Multiple Medical Meeting Presentations Focused on the Advantages of Suprachoroidal Delivery and Key Differentiators in its CLS-AX Clinical Program

Jan 22, 2025, 7:05 AM EST - 5 months ago

Clearside Biomedical Announces its Asia-Pacific Partner, Arctic Vision, Received Approval of Suprachoroidal Treatment for Uveitic Macular Edema in Australia and Singapore

Dec 19, 2024, 7:05 AM EST - 6 months ago

Clearside Biomedical Announces Publication of Critical Insights into Retinal Drug Development in the Peer-Reviewed Scientific Journal, Eye

Nov 25, 2024, 7:05 AM EST - 7 months ago

Clearside Biomedical Extends Global Footprint with Numerous Presentations at Medical Meetings in Asia, Europe and the United States

Nov 12, 2024, 8:37 PM EST - 7 months ago

Clearside Biomedical, Inc. (CLSD) Q3 2024 Earnings Conference Call Transcript

Nov 7, 2024, 9:05 AM EST - 8 months ago

Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema

Nov 6, 2024, 7:05 AM EST - 8 months ago

Clearside Biomedical to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference

Nov 4, 2024, 7:05 AM EST - 8 months ago

Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors

Oct 31, 2024, 7:05 AM EDT - 8 months ago

Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024

Oct 22, 2024, 7:05 AM EDT - 8 months ago

Clearside Biomedical's Positive ODYSSEY Wet AMD Data and Suprachoroidal Injection Platform Highlighted in Presentations at Multiple Events During AAO 2024 Annual Meeting

Oct 9, 2024, 6:30 AM EDT - 9 months ago

Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes

Aug 27, 2024, 7:05 AM EDT - 10 months ago

Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

Aug 8, 2024, 7:05 AM EDT - 11 months ago

Clearside Biomedical to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 1, 2024, 7:05 AM EDT - 11 months ago

Clearside Biomedical to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024

Jul 24, 2024, 11:23 PM EDT - 11 months ago

Clearside Biomedical, Inc. (CLSD) Suprachoroidal Space Drug Delivery (Transcript)

Jul 22, 2024, 12:00 PM EDT - 11 months ago

Clearside Biomedical Opens Registration for Suprachoroidal Delivery KOL Webinar to Be Held on Wednesday, July 24, 2024 at 8:00 am ET

Jul 11, 2024, 7:05 AM EDT - 1 year ago

Clearside Biomedical Appoints Dr. Glenn Yiu to its Scientific Advisory Board

Jun 27, 2024, 7:05 AM EDT - 1 year ago

Clearside Biomedical to Host Virtual Key Opinion Leader Event on the Use and Versatility of Suprachoroidal Drug Delivery

Jun 25, 2024, 12:54 PM EDT - 1 year ago

Why Is Clearside Biomedical Stock Gaining Today?

Jun 12, 2024, 7:05 AM EDT - 1 year ago

Clearside Biomedical's Leadership in Suprachoroidal Delivery Featured in Multiple Presentations at the Clinical Trials at the Summit Meeting

May 21, 2024, 7:05 AM EDT - 1 year ago

Clearside Biomedical Announces Publication of Consensus Guidelines for Drug Delivery via Suprachoroidal Space (SCS®) Injection in Leading Peer-Reviewed Industry Journal, RETINA®

May 9, 2024, 9:14 PM EDT - 1 year ago

Clearside Biomedical, Inc. (CLSD) Q1 2024 Earnings Call Transcript

May 9, 2024, 4:05 PM EDT - 1 year ago

Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 8, 2024, 4:15 PM EDT - 1 year ago

Clearside Biomedical to Participate in Fireside Chat at the Citizens JMP Life Sciences Conference

Apr 30, 2024, 7:05 AM EDT - 1 year ago

Clearside Biomedical to Report First Quarter 2024 Financial Results and Provide Corporate Update on Thursday, May 9, 2024

Apr 16, 2024, 7:05 AM EDT - 1 year ago

Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors

Apr 2, 2024, 7:05 AM EDT - 1 year ago

Clearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

Mar 18, 2024, 7:05 AM EDT - 1 year ago

Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer

Mar 13, 2024, 12:47 AM EDT - 1 year ago

Clearside Biomedical, Inc. (CLSD) Q4 2023 Earnings Call Transcript

Mar 12, 2024, 4:05 PM EDT - 1 year ago

Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Feb 29, 2024, 7:05 AM EST - 1 year ago

Clearside Biomedical to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on Tuesday, March 12, 2024

Feb 7, 2024, 8:00 AM EST - 1 year ago

Clearside Biomedical Announces Pricing of $15 Million Registered Direct Offering

Dec 14, 2023, 7:05 AM EST - 1 year ago

Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

Nov 13, 2023, 7:18 PM EST - 1 year ago

Clearside Biomedical, Inc. (CLSD) Q3 2023 Earnings Call Transcript

BioRich Jun. 21 at 3:58 AM

1 · Reply

BioRich Jun. 21 at 1:03 AM

1 · Reply

JWMM Jun. 20 at 8:03 PM

$CLSD big spike in volume and price at the close????

2 · Reply

BioRich Jun. 20 at 1:37 PM

$CLSD Does this have Phase 3 data readout tomorrow?

1 · Reply

Qora Jun. 19 at 2:06 PM

$CLSD wanted to start a discussion on other suprachoroidal delivery devices companies filed patents for. Implications of this vs. the breadth of SCS patents that Clearside has.

2 · Reply

maphere Jun. 19 at 1:12 PM

1 · Reply

rando321456 Jun. 18 at 8:01 AM

1 · Reply

maphere Jun. 17 at 2:34 PM

2 · Reply

maphere Jun. 15 at 12:45 AM

1 · Reply

wishpotion Jun. 13 at 2:33 PM

0 · Reply

valueforme Jun. 13 at 2:19 AM

$CLSD This is still one of the strangest bio microcaps on the market. Stock from 90s: CEO and CFO from 90s, Kansas City ophthalmologist with 5%+ stake, value investor Bradford Whitmore with 5%+ stake.. Great injector tech but no broad recognition by eye care docs, no new molecules but repurposing and reformulations of good old sfuff . Victor Chong , CMO, who saw all modern approvals of wet AMD drugs... The Stocktwits board full of smart people, not degenerates. And $0.80 per share . Hopefully we'll be paid here one day.

2 · Reply

maphere Jun. 11 at 2:31 PM

$CLSD What's the feasibility that CLSD sells their patents related to gene therapy via the SCS to ABBV / RGNX, plus receives a portion of all potential future milestones and a one-time royalty payment and virtually ending their connection to these companies? If so, what type of $$$ would they earn? $100,000,000 for the patents, $50,000,000 for milestones, and another $50,000,000 one-time royalty payment on future sales of RGX314??? They move forward as an independent company and can run the CLS-AX trials, pay off some debt, and create future licenses for small molecules and complement inhibitors against GA and other diseases? Thoughts?

4 · Reply

jbal Jun. 11 at 2:25 AM

$CLSD not sure how I missed it, Gibney is now CFO of AURA. Since 5/15.

4 · Reply

SNOB_ORDER Jun. 10 at 8:25 PM

$CLSD no interest ...to short the shares

0 · Reply

ThomasLD Jun. 10 at 6:57 PM

$CLSD BO?

0 · Reply

maphere Jun. 10 at 5:21 PM

$CLSD OIS Retina 2025 is July 29th. As I posted before, CLSD not on the Agenda or Speaker list (both OCUL and EYPT are). CLSD goes to OIS conferences all the time, they are a staple in the program...even UNeedle is at this upcoming one. Why not represent: 1. Cost (flying Victor to LA for a couple days)...nah. 2. They don't see the relevance (nothing new to present)...maybe but your competitors are there so it looks bad. 3. Phasing out the company if deal doesn't go thru soon...doubt it and glad to see the X post today. 4. Won't be owners of the SCS or CLS-AX program by then...wishful thinking on my part...maybe. 5. Whatever @clownmarket thinks... ;-) https://ois.net/retina-innovation-summit-presenting-companies/

2 · Reply

maphere Jun. 10 at 5:05 PM

$CLSD New X post from CLSD, keeping the message out there... https://x.com/clearsidebio/status/1932475490025222549

0 · Reply

US_Bull Jun. 10 at 4:11 PM

$CLSD To some of the longs here what am I missing a market cap of nearly 58 million with FDA approved drug and tons of partnerships and a great pipeline. I would say this company is a prime BO target if only institutional ownership was greater.

1 · Reply

edvquye Jun. 10 at 4:07 PM

$CLSD in $0.785

0 · Reply

clownmarket Jun. 10 at 1:54 PM

$CLSD Unusual volume again, this time during cash open. As far as I can see the biggest trade here (100k) was a buy Let's see her green on a couple million volume at least I'm still not positive about this action until we see an obvious sign like that

2 · Reply

BearishNinjaTrader Jun. 9 at 7:15 PM

$CLSD got the short call at $1.12 and didn’t disappoint 📉🔥 Another clean setup from our scalping channel — caught it before the drop. #CLSD #ShortSelling #Scalping #DayTrading #BearishNinja

1 · Reply

US_Bull Jun. 9 at 6:22 PM

$CLSD Starter with 15,985 shares volume is exploding.

0 · Reply

Market Cap	61.39M
Revenue (ttm)	1.66M
Net Income (ttm)	-34.35M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,069.28%
Debt to Equity Ratio	0.00

Volume	938,600
Avg Vol	260,866
Day's Range	N/A - N/A
Shares Out	77.71M
Stochastic %K	92%
Beta	2.06
Analysts	Strong Sell
Price Target	$5.43